Communications Biology (May 2021)
Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy
- Katrina Kildey,
- Neha S. Gandhi,
- Katherine B. Sahin,
- Esha T. Shah,
- Eric Boittier,
- Pascal H. G. Duijf,
- Christopher Molloy,
- Joshua T. Burgess,
- Sam Beard,
- Emma Bolderson,
- Amila Suraweera,
- Derek J. Richard,
- Kenneth J. O’Byrne,
- Mark N. Adams
Affiliations
- Katrina Kildey
- Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute
- Neha S. Gandhi
- Institute of Health and Biomedical Innovation, School of Mathematical Sciences, Faculty of Science and Engineering, Queensland University of Technology
- Katherine B. Sahin
- Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute
- Esha T. Shah
- Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute
- Eric Boittier
- Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute
- Pascal H. G. Duijf
- Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute
- Christopher Molloy
- Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute
- Joshua T. Burgess
- Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute
- Sam Beard
- Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute
- Emma Bolderson
- Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute
- Amila Suraweera
- Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute
- Derek J. Richard
- Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute
- Kenneth J. O’Byrne
- Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute
- Mark N. Adams
- Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute
- DOI
- https://doi.org/10.1038/s42003-021-02136-8
- Journal volume & issue
-
Vol. 4,
no. 1
pp. 1 – 12
Abstract
Kildey et al find that high levels of mitotic regulator CDCA3 correlates with sensitivity to platinum agents in non-small cell lung cancer patients and cell lines. They show that interfering with CDCA3 degradation through CK2 inhibition enhances CDCA3 levels and increases sensitivity to platinum agents suggesting a therapeutic route.
